Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers

Vox Sanguinis

Volumn 103, Issue 3, 2012, Pages 213-222

  Yver, A ^a   Homery, M C ^b   Fuseau, E ^c   Guemas, E ^a   Dhainaut, F ^a   Quagliaroli, D ^a   Beliard, R ^a   Prost, J F ^a  

^a LFB Biotechnologies   (France)

^b EMF Consulting ^*

^c EMF Consulting   (France)

Author keywords

Antibody function; Clinical trial; Immunoglobulins; Recombinant proteins

Indexed keywords

FC RECEPTOR; RHESUS D ANTIBODY; ROLEDUMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIMB PAIN; MACULOPAPULAR RASH; MALE; MUSCLE SPASM; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PITYRIASIS ROSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED; RECEPTORS, IGG; RECOMBINANT PROTEINS; RH-HR BLOOD-GROUP SYSTEM; YOUNG ADULT;

EID: 84866436795     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01603.x     Document Type: Article

References (31)

1. Levine P, Katzin EM, Burnham L: Isoimmunization in pregnancy: its possible bearing on the etiology of erythroblastosis fetalis. JAMA 1941; 116:825-827
2. Chown B: Anaemia from bleeding of the fetus into the mother's circulation. Lancet 1954; 266:1213-1215
3. Avent ND, Reid ME: The Rh blood group system: a review. Blood 2000; 95:375-387
4. Pollack W, Gorman JG, Freda VJ, et al.: Results of clinical trials of RhoGAM in women. Transfusion 1968; 8:151-153
5. Urbaniak SJ, Greiss MA: RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000; 14:44-61
6. Chilcott J, Lloyd Jones M, Wight J, et al.: A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003; 7:iii-62
7. EU Committee of Ministers: Recommendation N° R(90) 9 of the Committee of Ministers to Member States on Plasma Products and European Self-Sufficiency. Brussels, European Union, 1990
8. World Health Organisation: Towards 100% Voluntary Blood Donation. A Global Framework for Action. Geneva, WHO, 2010
9. Beliard R: Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol 2006; 13:58-64
10. Miescher S, Spycher MO, Amstutz H, et al.: A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 2004; 103:4028-4035
11. Olovnikova NI, Belkina EV, Berkovskii AL, et al.: [Monoclonal anti-D immunoglobulin for prevention of hemolytic disease of the newborn]. Gematol Transfuziol 1994; 39:3-6
12. Kumpel BM: In vivo studies of monoclonal anti-D and the mechanism of immune suppression. Transfus Clin Biol 2002; 9:9-14
13. Olovnikova NI, Ershler MA, Belkina EV, et al.: Effect of producer cell line on functional activity of anti-D monoclonal antibodies destined for prevention of rhesus sensitization. Bull Exp Biol Med 2009; 147:448-452
14. Kumpel BM: Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93:99-111
15. Abès R, Teillaud JL: Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010; 3:146-157
16. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al.: Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140:635-643
17. Beliard R, Waegemans T, Notelet D, et al.: A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141:109-119
18. Siberil S, de Romeuf C, Bihoreau N, et al.: Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 2006; 118:170-179
19. Mollison PL, Hughes-Jones NC: Clearance of Rh-positive red cells by low concentrations of Rh antibody. Immunology 1967; 12:63-73
20. Scott M: Section 1A: Rh serology. Coordinator's report. Transfus Clin Biol 2002; 9:23-29
21. Thorpe SJ, Fox B, Turner C, et al.: Competitive enzyme-linked immunoassay of monoclonal immunoglobulin G anti-D preparations. Transfus Med 2003; 13:153-159
22. Frandsen TP, Naested H, Rasmussen SK, et al.: Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108:2171-2181
23. Committee for Medicinal Products for Human Use: Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. London, EMA, 2007
24. Mire-Sluis AR, Barrett YC, Devanarayan V, et al.: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289:1-16
25. EMEA/CHMP: Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. London, EMEA/CHMP, 2007
26. Miller KJ, Bowsher RR, Celniker A, et al.: Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res 2001; 18:1373-1383
27. Food and Drugs Administration: Guidance for Industry, Bioanalytical Method Validation. Rockville, USA, U.S. Department of Health and Human Services, 2001
28. Suntharalingam G, Perry MR, Ward S, et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028
29. Jilma-Stohlawetz P, Reiter RA, Panzer S, et al.: Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. Transfus Apher Sci 2005; 33:135-140
30. Bichler J, Schondorfer G, Pabst G, et al.: Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG 2003; 110:39-45
31. Bichler J, Spycher MO, Amstutz HP, et al.: Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Transfus Med 2004; 14:165-171